Exclusive Webinar :Gain complete knowledge about how you can invest in global markets during an insightful webinar on April 16 at 11 am. Register Now!

Defaults among fragile emerging market firms set to rise: Moody's

"The global spread of the coronavirus has led to business closures and restrictions on social interactions in many countries," Moody's said in a report.

April 30, 2020 / 10:40 PM IST

Defaults by weaker emerging market companies will rise in 2020 and 2021 as the effect of the COVID-19 pandemic hampers business activity, Moody's forecast on Thursday.

The ratings agency said the trailing 12-month speculative-grade default rate for emerging market firms would rise to between 7.8% and 11.2% by the end of 2020, from the low level of 2.2% in March.

The rate will then rise further by March 2021 to the 8.3% to 13.7% range, it forecast.

"The global spread of the coronavirus has led to business closures and restrictions on social interactions in many countries," Moody's said in a report.

"The collapse in domestic aggregate demand and export demand has weakened EM (emerging market) corporate profitability and liquidity."

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Many low-rated emerging market governments were poorly prepared to deal with a large public health crisis and had limited fiscal and monetary capacity to stimulate their economies, it said.

Depressed oil prices will likely persist during the year, adding another strain to exporters of the commodity, it added.

 
Reuters
first published: Apr 30, 2020 10:38 pm

stay updated

Get Daily News on your Browser
Sections